LIFETECH SCI.DL-00000125 Net Assets
LIFETECH SCI.DL-00000125 net assets. Based on the latest financial reports, LIFETECH SCI.DL-00000125 (81X) has net assets worth €3.48 Billion EUR (≈ $4.06 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€5.01 Billion ≈ $5.86 Billion USD) and total liabilities (€1.54 Billion ≈ $1.80 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore LIFETECH SCI.DL-00000125 annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.48 Billion |
| % of Total Assets | 69.33% |
| Annual Growth Rate | 8.26% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 6.41 |
Net Assets of LIFETECH SCI.DL-00000125 (2021–2025)
Net assets of LIFETECH SCI.DL-00000125 from 2021 to 2025. This chart illustrates how LIFETECH SCI.DL-00000125's net assets have evolved over time, based on quarterly financial data. See LIFETECH SCI.DL-00000125 (81X) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for LIFETECH SCI.DL-00000125 (2021–2025)
The table below shows the annual net assets of LIFETECH SCI.DL-00000125 from 2021 to 2025. For live market cap and overall valuation, see LIFETECH SCI.DL-00000125 (81X) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €3.48 Billion ≈ $4.06 Billion |
-0.01% |
| 2024-12-31 | €3.48 Billion ≈ $4.06 Billion |
+4.56% |
| 2023-12-31 | €3.32 Billion ≈ $3.89 Billion |
+13.79% |
| 2022-12-31 | €2.92 Billion ≈ $3.42 Billion |
+15.45% |
| 2021-12-31 | €2.53 Billion ≈ $2.96 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to LIFETECH SCI.DL-00000125's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 90.1% over the analyzed period, indicating profitable operations and earnings retention.
LIFETECH SCI.DL-00000125 Net Assets Breakdown (December 2025)
LIFETECH SCI.DL-00000125 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €2.02 Billion | 57.58% |
| Other Components | €1.49 Billion | 42.42% |
| Total Equity | €3.51 Billion | 100.00% |
LIFETECH SCI.DL-00000125 Competitors by Market Cap
The table below lists competitors of LIFETECH SCI.DL-00000125 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Santacruz Silver Mining Ltd.
V:SCZ
|
$848.92 Million |
|
Tongyang Inc
KO:001525
|
$849.15 Million |
|
Wuzhou Special Paper Group Co. Ltd.
SHG:605007
|
$849.29 Million |
|
Gujarat Pipavav Port Limited
NSE:GPPL
|
$849.48 Million |
|
Nantong Jinghua Pharmaceutical Co Ltd
SHE:002349
|
$848.91 Million |
|
PARATUS ENERGY SERVICES LTD
OL:PLSV
|
$848.51 Million |
|
Mirae Asset Daewoo Co Ltd Pref
KO:00680K
|
$848.26 Million |
|
ShuYu Civilian Pharmacy Corp. Ltd.
SHE:301017
|
$848.16 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LIFETECH SCI.DL-00000125's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,494,507,000 to 3,512,647,000, a change of 18,140,000 (0.5%).
- Net income of 147,827,000 contributed positively to equity growth.
- Other factors increased equity by 259,364,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €147.83 Million | +4.21% |
| Other Changes | €259.36 Million | +7.38% |
| Total Change | €- | 0.52% |
Book Value vs Market Value Analysis
This analysis compares LIFETECH SCI.DL-00000125's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.21x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.54 | €0.17 | x |
| 2022-12-31 | €0.63 | €0.17 | x |
| 2023-12-31 | €0.77 | €0.17 | x |
| 2024-12-31 | €0.79 | €0.17 | x |
| 2025-12-31 | €0.80 | €0.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LIFETECH SCI.DL-00000125 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.21%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.79%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.43x
- Recent ROE (4.21%) is below the historical average (8.26%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 11.68% | 31.61% | 0.29x | 1.27x | €42.11 Million |
| 2022 | 11.22% | 29.65% | 0.30x | 1.27x | €35.29 Million |
| 2023 | 7.81% | 20.77% | 0.27x | 1.39x | €-73.78 Million |
| 2024 | 6.36% | 17.06% | 0.27x | 1.40x | €-127.06 Million |
| 2025 | 4.21% | 10.79% | 0.27x | 1.43x | €-203.44 Million |
Industry Comparison
This section compares LIFETECH SCI.DL-00000125's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $41,410,799,518
- Average return on equity (ROE) among peers: -32.95%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LIFETECH SCI.DL-00000125 (81X) | €3.48 Billion | 11.68% | 0.44x | $848.92 Million |
| LEPU MED.T.B. SP.GDR O.N. (07Z0) | $17.76 Billion | 5.42% | 0.47x | $168.20K |
| BIORETEC OY (0TN) | $9.76 Million | -97.14% | 0.20x | $16.10 Million |
| SYSMEX CORP.UNSP.ADR 1/2 (0YX0) | $388.36 Billion | 11.79% | 0.37x | $4.70 Billion |
| INMODE LTD IS -01 (154) | $683.20 Million | 13.73% | 0.12x | $711.77 Million |
| HeraMED Limited (1I4) | $2.59 Million | -168.10% | 0.60x | $27.68 Million |
| Medtronic PLC (2M6) | $1.75 Billion | 30.35% | 0.38x | $83.04 Billion |
| Peijia Medical Limited (4WO) | $3.02 Billion | -19.02% | 0.05x | $305.26 Million |
| AVITA Medical Inc (51KB) | $84.74 Million | -31.47% | 0.16x | $172.49 Million |
| BRAINCOOL AB (5YL) | $111.74 Million | -54.84% | 0.19x | $18.88 Million |
| MICROPORT CARDIO.MEDTECH. (72X) | $2.33 Billion | -20.20% | 0.10x | $107.57 Million |
About LIFETECH SCI.DL-00000125
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders in Mainland China, Europe, Rest of Asia, India, South America, Africa, and internationally. It operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac P… Read more